MECHELEN, BELGIUM--(Marketwire -09/02/12)- Galapagos NV (GLPGF) announcedtoday that its service division BioFocus and Ono Pharmaceutical Co., Ltd.(OsakaJapan) have signed a new collaboration agreement, focused on discoveringnoveldrugs in the field of CNS disorders. Under the new agreement, BioFocuswill useits drug discovery platform to deliver leads and clinical candidatesfor itsclient. Financial details were undisclosed.
"We are delighted to have this new agreement, which is the first drugdiscoveryprogram with this, a most valued, client" said Dr. Chris Newton, SVPGalapagosServices and Managing Director of BioFocus. "This project plays toBioFocushistoric strengths and the expanding breadth and depth of thispartnership istestament to a tried and trusted relationship."
Kazuhito Kawabata, Ph.D., Member of the Board of Directors, ExecutiveOfficerand Executive Director, Discovery and Research of Ono commented: "Wehave thehighest regard for the BioFocus' comprehensive drug discovery platform.Thiscollaboration will strengthen Ono's drug discovery capability in thefield ofCNS disorders with significant unmet medical needs and we are expectingthatinnovative drugs will be created through this collaboration."
BioFocus provides integrated drug discovery that delivers pre-clinicaldrugcandidates in all therapeutic areas with strong capability inneurodegenerativediseases, inflammatory diseases and with a growing track record ofdeliveringcandidates against rare and neglected diseases. BioFocus hasadvanced andcomprehensive drug discovery capabilities that are applied to clientprojects todeliver targets, hits, leads and candidate pre-clinical drugs. Thecompanyemploys over 250 exceptionally qualified and industry experiencedscientists atits three research centers in the UK, Switzerland and the Netherlands.Sinceits foundation in 1997, BioFocus has striven to produce high qualitydata forits clients and this quality is assured by ISO9001 qualificationvalidated byregular, independent inspection of all BioFocus research centers. Formoreinformation please visit www.biofocus.com.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinicalstagebiotechnology company specialized in the discovery and development ofsmallmolecule and antibody therapies with novel modes-of-action. TheCompany isprogressing its JAK1 inhibitor GLPG0634, as well as one of the largestpipelinesin biotech, with four programs in development and over 30 discoveryprograms. The Galapagos Group has about 800 employees and operates facilitiesin sixcountries, with global headquarters in Mechelen, Belgium. Moreinfo at:www.glpg.com
In keeping with its philosophy of "Dedicated to Man's Fight againstDisease andPain," Ono has always striven to achieve its goal of serving as an R&D-orientedglobal specialty pharmaceuticals, aiming to develop innovative andgloballyrecognized drugs. To do this, Ono has been engaged in drug discoveryresearchbased on accumulated technologies and know-how - in areas where itsstrengthscan be fully exploited (i.e. bioactive lipid agonists and enzyme inhibitorssuchas proteases and kinases). In addition, modulators of membranetransportsystems such as ion-channels and transporters as well as biotechnology-basedmedicines are also the areas of our focus where we drive forward ourresearcheffectively deploying our know-how from neuroscience research and ourgeneassets together with the latest information acquired from globalresearchinstitutions on drug discovery targets and the cutting-edge drugdiscoverytechnologies that biopharmaceutical companies can offer. For moreinformation,please visit www.ono.co.jp.
This release may contain forward-looking statements, including,withoutlimitation, statements containing the words "believes,""anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could,""stands to," and "continues," as well as similar expressions. Suchforward-looking statements may involve known and unknown risks, uncertainties andotherfactors which might cause the actual results, financial condition,performanceor achievements of Galapagos, or industry results, to be materiallydifferentfrom any historic or future results, financial conditions,performance orachievements expressed or implied by such forward-looking statements.Giventhese uncertainties, the reader is advised not to place any unduereliance onsuch forward-looking statements. These forward-looking statements speakonly asof the date of publication of this document. Galapagos expresslydisclaims anyobligation to update any such forward-looking statements in thisdocument toreflect any change in its expectations with regard thereto or anychange inevents, conditions or circumstances on which any such statement is based,unlessrequired by law or regulation.
BioFocus(®) is a trademark of Galapagos NV and/or its affiliates© Copyright2012 Galapagos NV.
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
- drug discovery
Dr Chris Newton
SVP Galapagos Services
Tel: +44 1799 533 535
Director Investor Relations
Tel: +31 62 291 6240